From Here to JUPITER
This article evaluates the potential impact of findings from the study Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluation Rosuvastatin (JUPITER). Research from JUPITER indicates that statin therapy may be effective for people who have normal levels of lipoproteins but elevated high-sensitivity C-reactive protein levels. This article identifies the size and characteristics of the population that may be impacted by the findings from JUPITER.
The authors used data from the National Health and Nutrition Survey (1999–2004) to identify the population already using statin therapy and the population that would be eligible for statin therapy given the new findings from JUPITER.
- Almost 20 percent of older Americans may become eligible for statin therapy due to the JUPITER findings.
- People newly eligible for statin therapy are disproportionately likely to be female, older, obese, hypertensive and have metabolic syndrome.
Almost 60 percent of older Americans are currently indicated for statin therapy. The expanded population for statin therapy would approach 80 percent of Americans over 50 years of age.